Determining the optimal timing of disease-modifying therapies for neurodegenerative disorders will necessitate identification of when the underlying pathobiological process becomes active, well in advance of the point at which clinical manifestions appear. Phenoconversion, the emergence of clinically manifest syndomes,...
Michael J. Strong, Neil S. Donison, A. Al-Chalabi et al.· Brain : a journal of neurolo...· 0 citations
Background and Objectives Early-onset Alzheimer disease (EOAD) is associated with substantial variability in clinical progression, and reliable biomarkers to predict the transition from mild cognitive impairment (MCI) to dementia remain limited. Structural MRI measures have demonstrated prognostic value in late-onset A...
T. Paranhos, Yuta Katsumi, M. Brickhouse et al.· Neurology· 0 citations
In this case report, areas of extensive amyloid clearance following amyloid targeting therapy were associated with less downstream neuropathological change and appear to preferentially occur in gyral crests.
Christopher A. Brown, John L. Robinson, Sandhitsu R. Das et al.· Journal of the American Medi...· 0 citations
BACKGROUND AND OBJECTIVES
Histopathologic staging of Alzheimer disease has led to validation of imaging techniques that guide diagnosis and treatment. We previously constructed preliminary phases of the sequential progression of TDP-43 and tau to guide similar efforts in behavioral-variant frontotemporal dementia (bvFT...
R. Magee, Sharon X. Xie, DT Ohm et al.· Neurology· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
